FDA Rejects Sparlon Due To Single SJS Case; An Ominous Sign For Pharma?
Executive Summary
FDA's decision that Cephalon's attention deficit hyperactivity disorder treatment Sparlon is not approvable - based on an adverse event in a single patient - could be indicative of a more challenging regulatory environment for manufacturers